Celltrion Wins U.S. PBM Preferred Status for Autoimmune Biosimilar

SEOUL, Dec. 12 (Korea Bizwire) — Celltrion Inc. said Friday that its autoimmune biosimilar Avtozma has been added to the preferred drug list of Synergie Collective, one of the five largest pharmacy benefit managers in the United States—an endorsement that could significantly widen the drug’s market access. The South Korean biopharmaceutical company said the agreement will [...]